Bio-Techne Corp. is acquiring Exosome Diagnostics Inc. to complement its existing Advanced Cellular Diagnostics (ACD) business with Exosome's biofluid-based diagnostics, and to take advantage of the emerging precision-medicine trend.
"Exosome Diagnostic's technology is a game-changer, and positions Bio-Techne to be a leader in the rapidly-growing noninvasive liquid biopsy market,"...